Our results demonstrate that immunotherapy with anti-EpCAM CAR-expressing T cells, either modified with lentiviral transduction or mRNA electroporation, can effectively suppress peritoneal tumor progression and, therefore, could potentially be used to treat late-stage PC. The gene discussed is EPCAM; the disease is pachyonychia congenita.